Stoke Therapeutics, Inc. Sustainability Profile
Stoke Therapeutics, Inc., a pioneering biotechnology company headquartered in the United States, focuses on developing innovative RNA-based therapies for severe genetic diseases. Founded in 2018, Stoke has quickly established itself in the biopharmaceutical industry, particularly in the field of genetic medicine. The company is renowned for its proprietary TANGO™ platform, which uniquely enhances the expression of specific genes to address the underlying causes of diseases. This cutting-edge approach sets Stoke apart in a competitive market, positioning it as a leader in the development of treatments for conditions such as epilepsy and other neurological disorders. With a commitment to advancing genetic therapies, Stoke Therapeutics continues to achieve significant milestones, solidifying its reputation as a key player in the biotechnology landscape.
DitchCarbon Score
How does Stoke Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Stoke Therapeutics, Inc.'s score of 36 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Stoke Therapeutics, Inc.'s reported carbon emissions
Stoke Therapeutics, Inc., headquartered in the US, has set ambitious climate commitments despite not having specific carbon emissions data available. The company has established science-based targets to significantly reduce its greenhouse gas emissions across various scopes. For the near term, Stoke aims to achieve a 42% reduction in Scope 1 and Scope 2 emissions by 2030, using 2023 as the baseline year. Looking towards the long term, the company has committed to a substantial 90% reduction in both Scope 1 and Scope 2 emissions by 2050. Additionally, Stoke has pledged to reach net-zero emissions across all scopes by 2050. These targets align with the 1.5°C climate goal, demonstrating Stoke's commitment to sustainable practices and climate responsibility. The company's initiatives reflect a proactive approach to addressing climate change and reducing its environmental impact.
How Carbon Intensive is Stoke Therapeutics, Inc.'s Industry?
How Carbon Intensive is Stoke Therapeutics, Inc.'s Location?
Stoke Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Stoke Therapeutics, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
